At GoBroad Healthcare Group, we are committed to pushing the boundaries of medical innovation. As an innovator in research-oriented hospitals, we strive to improve the diagnosis and treatment of complex diseases. One of our most significant recent achievements is the successful approval of our nuclear medicine program at Beijing GoBroad Hospital, which is set to revolutionize gastrointestinal cancer treatment.

Pioneering Nuclear Medicine for Gastrointestinal Cancer Treatment

Beijing GoBroad Hospital has always been contributing to advancements in treating complex and severe illnesses. Our strategic focus on clinical research and biopharmaceutical industry transformation has led us to a major breakthrough—securing approval for the clinical application of Lutetium-177 (Lu-177) based radiopharmaceutical therapy. This milestone underscores our dedication to medical innovation and positions us as a key player in advancing nuclear medicine in China.

China maintains stringent regulations on nuclear medicine applications, with rigorous approval conditions and complex review processes. Despite these challenges, our team successfully navigated the regulatory landscape, paving the way for new treatment possibilities for patients with gastrointestinal and pancreatic neuroendocrine tumors. This achievement is a testament to our unwavering commitment to pioneering advanced cancer therapies.

The Potential of PRRT in Cancer Care

One of the most promising applications of nuclear medicine in gastrointestinal cancer treatment is Peptide Receptor Radionuclide Therapy (PRRT) using Lu-177. Led by Professor Lu Ming from Beijing University Cancer Hospital and Beijing GoBroad Hospital, we are conducting a groundbreaking clinical trial to evaluate PRRT's efficacy in treating neuroendocrine tumors.

PRRT has emerged as a powerful therapeutic option, demonstrating significantly longer disease control compared to existing treatments. With its precise targeting mechanism, this therapy delivers radioactive particles directly to tumor cells while minimizing damage to surrounding healthy tissues. The potential benefits of PRRT offer new hope to patients and highlight the revolutionary impact of nuclear medicine in cancer care.

Conclusion

At GoBroad, we believe that cutting-edge research and advanced therapies are the key to transforming patient outcomes. The introduction of Lu-177-based PRRT is not just a medical advancement—it is a lifeline for those battling gastrointestinal cancers. Our team remains dedicated to refining this approach, ensuring that more patients can access state-of-the-art treatments that improve both survival rates and quality of life.

With every step forward, we reaffirm our mission to involve in the development of cancer treatment. By integrating innovative research with compassionate patient care, we continue to redefine what is possible in modern medicine. At GoBroad, we are not just treating diseases—we are shaping the future of healthcare.